Benitec Biopharma (BNTC) Insider Kevin Buchi Sells 51,813 Shares

Insider Buying and Selling at Benitec Biopharma Inc.

Kevin Buchi sold 51,813 shares of Benitec Biopharma Inc. (BNTC) on June 29, 2026. The shares were sold at a price of $13.38 each, reflecting a significant insider trade given the company's market cap of about $379.5 million. His sale represents a notable transaction, especially as insider trades can indicate confidence or concerns about a company's future prospects.

How Benitec Biopharma Inc. Stock Has Traded

Following the trade, Benitec Biopharma's stock is currently priced at $13.38. This price is above its 52-week low of $9.85 and below its high of $16.76, suggesting that the stock has had a fair amount of volatility in the past year. The stock's performance is essential as it reflects investor sentiment, especially in the biotechnology sector where companies can experience sharp changes based on clinical trial results and regulatory approvals.

Analysts Set New Price Targets

On September 15, 2026, Wedbush maintained its rating of Outperform on Benitec Biopharma with a price target of $17.00. Earlier, on July 28, 2026, the same firm initiated coverage with a rating of Outperform and a target of $16.00. The consensus among six analysts currently stands with a mean price target of $24.33, indicating strong confidence in the company's future prospects.

What Benitec Biopharma Inc. Does

Benitec Biopharma is a clinical-stage biotechnology firm based in Hayward, California. The company is focused on developing innovative genetic medicines, using a combination of RNA interference and gene therapy techniques. This strategic approach allows them to directly target disease-causing genes, which could lead to significant advancements in treatment options for various conditions.

What’s Next for Benitec

Benitec Biopharma's next earnings report is scheduled for November 12, 2026. Investors will likely keep a close watch on this announcement, as upcoming earnings can significantly impact stock prices. Additionally, it’s worth noting that insider transactions like Buchi's sale reflect past decisions and may not necessarily indicate future actions. As such, market watchers should consider both insider activity and analyst opinions as they assess Benitec's potential moving forward.